316 related articles for article (PubMed ID: 11770188)
1. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy.
Wu MH; Pan HA; Wang ST; Hsu CC; Chang FM; Huang KE
Climacteric; 2001 Dec; 4(4):314-9. PubMed ID: 11770188
[TBL] [Abstract][Full Text] [Related]
2. Effect on sexual life--a comparison between tibolone and continuous combined conjugated equine estrogens and medroxyprogesterone acetate.
Uygur D; Yeşildaglar N; Erkaya S
Gynecol Endocrinol; 2005 Apr; 20(4):209-12. PubMed ID: 16019363
[TBL] [Abstract][Full Text] [Related]
3. Effect of different preparations of hormone therapy on sexual dysfunction in naturally postmenopausal women.
Osmanağaoğlu MA; Atasaral T; Baltaci D; Bozkaya H
Climacteric; 2006 Dec; 9(6):464-72. PubMed ID: 17085380
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women.
Ziaei S; Moghasemi M; Faghihzadeh S
Climacteric; 2010 Apr; 13(2):147-56. PubMed ID: 19731119
[TBL] [Abstract][Full Text] [Related]
5. Flow resistance in carotid and middle cerebral arteries in postmenopausal women: a comparative study of tibolone and continuous combined hormone replacement therapy.
Pan HA; Wang ST; Chen CH; Pai MC; Wu MH; Huang KE
Climacteric; 2002 Sep; 5(3):259-65. PubMed ID: 12419084
[TBL] [Abstract][Full Text] [Related]
6. Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison.
Pan HA; Wang ST; Pai MC; Chen CH; Wu MH; Huang KE
J Reprod Med; 2003 May; 48(5):375-80. PubMed ID: 12815913
[TBL] [Abstract][Full Text] [Related]
7. Effects of tibolone and raloxifene on health-related quality of life and sexual function.
Nijland EA; Weijmar Schultz WC; Davis SR
Maturitas; 2007 Oct; 58(2):164-73. PubMed ID: 17870260
[TBL] [Abstract][Full Text] [Related]
8. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
[TBL] [Abstract][Full Text] [Related]
9. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women.
Diaby V; Perreault S; Lachaine J
Maturitas; 2007 Oct; 58(2):138-49. PubMed ID: 17870259
[TBL] [Abstract][Full Text] [Related]
10. Effect of hormone replacement therapy and tibolone on serum leptin levels in postmenopausal women.
Lambrinoudaki IV; Christodoulakos GE; Panoulis CP; Rizos DA; Dendrinos SG; Liakakos T; Augoulea AD; Creatsas GC
Maturitas; 2004 Jun; 48(2):107-13. PubMed ID: 15172084
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide in postmenopausal women taking three different HRT regimens.
Kesim MD; Aydin Y; Erdemir M; Atis A
Maturitas; 2005 Jan; 50(1):52-7. PubMed ID: 15590214
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.
Hudita D; Posea C; Ceausu I; Rusu M
Eur Rev Med Pharmacol Sci; 2003; 7(5):117-25. PubMed ID: 15214586
[TBL] [Abstract][Full Text] [Related]
13. Clitoral circulation in postmenopausal women with sexual dysfunction: a pilot randomized study with hormone therapy.
Nappi RE; Ferdeghini F; Sampaolo P; Vaccaro P; De Leonardis C; Albani F; Salonia A; Polatti F
Maturitas; 2006 Oct; 55(3):288-95. PubMed ID: 16730929
[TBL] [Abstract][Full Text] [Related]
14. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality.
Genazzani AR; Stomati M; Valentino V; Pluchino N; Pot E; Casarosa E; Merlini S; Giannini A; Luisi M
Climacteric; 2011 Dec; 14(6):661-8. PubMed ID: 21942655
[TBL] [Abstract][Full Text] [Related]
15. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of continuous combined hormone therapy and tibolone on body composition in postmenopausal women.
Ziaei S; Moaya M; Faghihzadeh S
Climacteric; 2010 Jun; 13(3):249-53. PubMed ID: 19848555
[TBL] [Abstract][Full Text] [Related]
17. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study.
Polisseni AF; Andrade AT; Ribeiro LC; Castro IQ; Brandão M; Polisseni F; Guerra Mde O
Maturitas; 2013 Feb; 74(2):172-8. PubMed ID: 23201326
[TBL] [Abstract][Full Text] [Related]
18. Conjugated estrogen/progestagen versus tibolone hormone replacement therapy in postmenopausal women: Effects on carbohydrate metabolism and serum sex hormone-binding globulin.
Odmark IS; Carlström K; Jonsson B; Jonasson AF
Maturitas; 2006 Jan; 53(1):89-96. PubMed ID: 15964160
[TBL] [Abstract][Full Text] [Related]
19. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Pueraria lobata with hormone replacement therapy in treating the adverse health consequences of menopause.
Woo J; Lau E; Ho SC; Cheng F; Chan C; Chan AS; Haines CJ; Chan TY; Li M; Sham A
Menopause; 2003; 10(4):352-61. PubMed ID: 12851519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
